Digging Through Arrowhead Pharmaceuticals, Inc. (ARWR) Fundamentals

On Thursday, shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) marked $48.85 per share versus a previous $44.46 closing price. With having a 9.87% gain, an insight into the fundamental values of Arrowhead Pharmaceuticals, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. ARWR showed a fall of -22.99% within its YTD performance, with highs and lows between $19.51 – $73.72 during the period of 52 weeks, compared to the simple moving average of 21.96% in the period of the last 200 days.

RBC Capital Mkts equity researchers changed the status of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) shares to a “Outperform” rating in the report published on May 13th, 2020. Other analysts, including Oppenheimer, also published their reports on ARWR shares. Oppenheimer repeated the rating from the previous report, marking ARWR under “Outperform” rating, in the report published on May 8th, 2020. Additionally, ARWR shares got another “Overweight” rating from Cantor Fitzgerald, setting a target price of $60 on the company’s shares, according to the report published in April 15th, 2020. On March 24th, 2020, SVB Leerink Upgrade an Mkt Perform rating and increased its price target to $29. On the other hand, Goldman Initiated the “Neutral” rating for ARWR shares, as published in the report on March 17th, 2020. SVB Leerink seems to be going bullish on the price of ARWR shares, based on the price prediction for ARWR, indicating that the shares will jump to $32, giving the shares “Underperform” rating based on their report from January 21st, 2020. Another “Perform” rating came from Oppenheimer.

Arrowhead Pharmaceuticals, Inc. (ARWR) Analysis

The present dividend yield for ARWR owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -35.80%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of Arrowhead Pharmaceuticals, Inc. (ARWR) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of -5.60% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 7.40 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while ARWR is currently recording an average of 1.39M in volumes. The volatility of the stock on monthly basis is set at 5.95%, while the weekly volatility levels are marked at 5.88%with 1.75% of gain in the last seven days. Additionally, long-term investors are predicting the target price of $65.64, indicating growth from the present price of $48.85, which can represent yet another valuable research and analysis points that can help you decide whether to invest in ARWR or pass.

What to Look for When Analyzing Arrowhead Pharmaceuticals, Inc. Shares?

Arrowhead Pharmaceuticals, Inc. (ARWR) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare ARWR shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for Arrowhead Pharmaceuticals, Inc., while the value can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -0.24 is supported by the yearly EPS growth of 205.90%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 3.70%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 67.90% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

Are Institutional Investors Increasing Stakes in ARWR Shares?

It appears that more than several institutional investors and hedge funds decided to increase stakes in ARWR in the recent period. That is how BlackRock Fund Advisors now has an increase position in ARWR by 3.28% in the first quarter, owning 11.55 million shares of ARWR stocks, with the value of $497.53 million after the purchase of an additional 367,298 shares during the last quarter. In the meanwhile, The Vanguard Group, Inc. also increased their stake in ARWR shares changed 0.68% in the first quarter, which means that the company now owns 9.4 million shares of company, all valued at $404.94 million after the acquisition of additional 63,507 shares during the last quarter.

SSgA Funds Management, Inc. acquired a new position in Arrowhead Pharmaceuticals, Inc. during the first quarter, with the value of $210.63 million, and Northern Trust Investments, Inc. increased their stake in the company’s shares by 4.05% in the first quarter, now owning 65,577 shares valued at $72.55 million after the acquisition of the additional 1.68 million shares during the last quarter. In the end, Geode Capital Management LLC increased their position by 68.80% during the first quarter, now owning 1.55 million ARWR shares, now holding the value of $66.93 million in ARWR with the purchase of the additional 38,813 shares during the period of the last quarter. At the present, 67.90% of ARWR shares are in the ownership of institutional investors.


Please enter your comment!
Please enter your name here